Who We Are
Moderna is a clinical stage pioneer of messenger RNA (mRNA) therapeutics and vaccines, an entirely new drug technology that directs the body’s cells to produce intracellular or secreted proteins.
With our breakthrough platform, we are developing this new class of medicines for a wide range of diseases and conditions, in many cases by addressing currently undruggable targets. Founded in 2010, we are headquartered in Cambridge, Mass.
Our Team and Mission
We currently have over 550 team members, an exceptional group of scientists and industry professionals who are wholly committed to advancing Moderna’s mission: deliver on the promise of mRNA science to create a new generation of transformative medicines for patients.
Our mRNA Technology Platform
mRNA carries instructions copied from DNA, which cells use to make proteins. Proteins perform virtually every biological function in the human body. Most diseases occur when too much or too little of a certain protein is produced.
Our mRNA technology acts as cellular software, directing the body’s cellular machinery to produce nearly any protein of interest. By getting inside the cell and getting the body to produce intracellular proteins, we have the potential to address many diseases that today aren’t druggable with small molecule drugs or biologics.
Rather than giving the body proteins as medicines, we give the body the genetic code (via mRNA) to produce its own proteins and become the factory for its medicine.
Our Strategy and Ecosystem
Our strategy is to advance a broad array of mRNA drugs for many diseases simultaneously to deliver on the promise of mRNA science for patients as quickly as possible.
We are developing innovative mRNA medicines for infectious diseases, cancer (immuno-oncology), rare liver diseases, cardiovascular diseases and pulmonary diseases, through both internal development and collaborations with strategic partners.
We have strategic agreements with AstraZeneca, Merck and Vertex Pharmaceuticals, as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS); and the Bill & Melinda Gates Foundation.
The Leader in mRNA Therapeutics
With our scientific understanding of mRNA medicines continuing to grow at an accelerated pace, we are investing heavily across the full breath of competencies needed to drive our platform forward, including chemistry, mRNA biology, formulation, automation and high-throughput production, process development, quality and Good Manufacturing Practices (GMP) mRNA clinical manufacturing.
Our Pipeline and Early Development Engine
Our pipeline currently includes 16 mRNA development candidates. Clinical studies for seven of these programs (five mRNA vaccines and two mRNA therapeutics) are already underway in the U.S., Europe and Australia, with the remaining nine programs advancing toward the clinic. In addition, we have several research programs advancing to the development stage. In the coming months and years, Moderna and our partners anticipate conducting many clinical studies across our therapeutic portfolio in parallel.
To support and manage this anticipated breadth of clinical studies, we are building a sophisticated, highly integrated early development engine designed to deliver the highest quality mRNA drugs from candidate nomination through to human proof-of-concept (PoC) data. A key component of our early development engine is our planned 200,000 square foot Good Manufacturing Practices (GMP) mRNA clinical manufacturing facility in Norwood, Mass. Anticipated to open in the summer of 2018, this facility will enable the manufacture, quality, control and supply of clinical grade mRNA therapies and vaccines for Good Laboratory Practices (GLP) toxicology studies as well as Phase 1 and Phase 2 clinical studies. At the site, we will carry out all manufacturing activities—from raw material production to active pharmaceutical ingredients (APIs), formulation, filling and finish.